Gravity Research

Avanir Pharmeceuticals (NASDAQ: AVNR) stock plummeted yesterday after Gravity Research said Avanir, “engaged in illegal off-label marketing of Nuedexta,” and recommended a strong Sell. Shares closed at $4.79 on Wednesday, a 13 percent decrease. This was the biggest drop of AVNR in three years...